Showing results (1131-1140 of 1,193) with videos related to
Sort By:
Pageof 120
Blood|June 29, 2012
Revised international prognostic scoring system for myelodysplastic syndromesPeter L Greenberg, Heinz Tuechler, Julie Schanz, et al.Cancer Cell|March 28, 2025
A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignanciesIoanna Mosialou, Abdullah M Ali, Rossella Labella, et al.JCO Oncology Practice|February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.Blood Advances|April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemiaAbhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.Blood Advances|July 11, 2025
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Sanam Loghavi, Ziyi Li, et al.Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.Cancer|November 25, 2024
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemiaWei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, et al.Nature Medicine|March 4, 2022
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.Nature Communications|February 8, 2024
Targeting DNA2 overcomes metabolic reprogramming in multiple myelomaNatthakan Thongon, Feiyang Ma, Natalia Baran, et al.Pageof 120